Establishment of BALB/C mouse models of influenza A H1N1 aerosol inhalation

2019 ◽  
Vol 91 (11) ◽  
pp. 1918-1929
Author(s):  
Xin‐Yan Hao ◽  
Feng‐Di Li ◽  
Qi Lv ◽  
Yan‐Feng Xu ◽  
Yun‐Lin Han ◽  
...  
Keyword(s):  
Mouse Models ◽  
Influenza A ◽  
Aerosol Inhalation ◽  
Influenza A H1n1

scholarly journals 162. CD377, a Novel Antiviral Fc-conjugate, Demonstrates Potent Viral Burden Reduction Against Influenza a (H1N1) in Mouse and Ferret Models

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S210-S211
Author(s):  
Simon Döhrmann ◽  
Amanda Almaguer ◽  
Nicholas Dedeic ◽  
Karin Amundson ◽  
Kim Shathia ◽  
...  
Keyword(s):  
Viral Load ◽  
Mouse Models ◽  
Influenza A ◽  
Post Challenge ◽  
Lung Burden ◽  
Influenza A H1n1 ◽  
Prevention And Treatment ◽  
2009 H1n1 ◽  
Dose Ranging ◽  
Dose Dependent

Abstract Background AVCs (antiviral Fc-conjugates) are novel, long-acting immunotherapeutic conjugates of potent antivirals conjugated to the Fc domain of human IgG1. CD377, an AVC development candidate for the prevention and treatment of influenza A and B, comprises multiple copies of a novel neuraminidase inhibitor conjugated to IgG1 Fc. CD377 demonstrated potent, broad-spectrum activity in vitro and in lethal mouse models. Herein, we characterize the activity of CD377 on viral lung burden in lethal mouse models and in a ferret model of influenza A (H1N1) infection. Methods BALB/c mice were challenged intranasally with 3 x 102 PFU of influenza A/PR/8/1934 (H1N1) or with 3 x 104 PFU A/CA/07/2009 (H1N1)pdm. Ferrets were challenged sub-lethally at 1 x 106 PFU with influenza A/CA/07/2009 (H1N1)pdm. A single dose of CD377 was given 2 h post-challenge in the mouse (subcutaneous dose ranging from 0.1 – 3 mg/kg) or 24 h prior to challenge in the ferret (intravenous dose ranging from 0.3 – 30 mg/kg). In mice, oral oseltamivir was given at 5 mg/kg (human equivalent dose, HED) or at 50 mg/kg BID x 4 days starting at 2 h post-challenge and in ferrets at 20 mg/kg (4x HED) BID x 4 days starting at 4 h prior to infection. Viral burden was determined on day 4 (mouse) or days 2 and 4 (ferret) post-challenge by plaque assay. Results In mice, CD377 demonstrated dose-dependent reduction in viral lung burden (1.1 logs at 0.1 mg/kg, 2.1 logs at 0.3 mg/kg, 3.1 logs at 1 mg/kg and 3.6 logs at 3 mg/kg) compared to PBS against influenza A/PR/8/1934 (H1N1) (Fig. 1A). In the same study, oseltamivir reduced viral lung burden only by 0.8 logs at both 5 mg/kg (HED) and 50 mg/kg. No significant reduction in lung burden was observed between negative controls, PBS and hIgG1 Fc. Similarly, CD377 demonstrated a dose-dependent, multi-log reduction in viral lung burden against influenza A/CA/07/2009 (H1N1)pdm (Fig. 1B). In ferrets, CD377 reduced viral load with dose dependency at days 2 (Fig. 1C) and 4 post-infection (Fig. 1D). CD377 at 3 mg/kg or higher dose was superior compared to oseltamivir at 4x HED on days 2 and 4 post-challenge. Conclusion CD377 demonstrated superior viral load reduction compared to oseltamivir in lethal influenza A (H1N1) mouse and ferret models. These data support further development of CD377 for prevention and treatment of influenza infection. Disclosures Simon Döhrmann, PhD, Cidara Therapeutics (Shareholder) Amanda Almaguer, Bachelors, Cidara Therapeutics, Inc. (Employee, Shareholder) Nicholas Dedeic, n/a, Cidara Therapeutics (Employee) Karin Amundson, BSc, Cidara Therapeutics (Shareholder) Thomas P. Brady, PhD Chemistry, Cidara Therapeutics (Employee) Alain Noncovich, PhD, Cidara Therapeutics (Shareholder) Grayson Hough, MS - Chemistry, Cidara Therapeutics (Employee) Allen Borchardt, PhD, Cidara Therapeutics (Employee) Jeffrey B. Locke, PhD, Cidara Therapeutics, Inc. (Employee, Shareholder) Jason Cole, PhD, Cidara Therapeutics (Shareholder) James Levin, PhD, Cidara Therapeutics (Shareholder) Les Tari, PhD, Cidara Therapeutics (Shareholder)

Adaptation of influenza A(H1N1)pdm09 virus in experimental mouse models

2016 ◽  
Vol 39 ◽  
pp. 265-271 ◽  
Author(s):  
E.A. Prokopyeva ◽  
I.A. Sobolev ◽  
M.V. Prokopyev ◽  
A.M. Shestopalov
Keyword(s):  
Mouse Models ◽  
Influenza A ◽  
Pdm09 Virus ◽  
Influenza A H1n1 ◽  
Experimental Mouse

Neurologic and Muscular Complications of the 2009 Influenza A (H1N1) Pandemic

2011 ◽  
Vol 2011 ◽  
pp. 129-130
Author(s):  
A. Verma
Keyword(s):  
Influenza A ◽  
H1n1 Pandemic ◽  
Influenza A H1n1

Diagnostic Wrinkles Anticipated in Novel Influenza A (H1N1) Pandemic

2009 ◽  
Vol 39 (15) ◽  
pp. 22
Author(s):  
BRUCE JANCIN
Keyword(s):  
Influenza A ◽  
H1n1 Pandemic ◽  
Influenza A H1n1 ◽  
Novel Influenza A

Nachweis bakterieller Superinfektionen bei Patienten mit Influenza A H1N1 mithilfe kultur-unabhängiger molekulargenetischer Typisierung

2010 ◽  
Vol 222 (S 01) ◽  
Author(s):  
M Schiller ◽  
S Eva ◽  
A Halfmann ◽  
HJ Schäfers ◽  
B Gärtner ◽  
...  
Keyword(s):  
Influenza A ◽  
Influenza A H1n1

Protective effect of orally administered Spirulina braun-type lipoproteins against influenza A (H1N1) virus infection in mice

Planta Medica ◽  
2014 ◽  
Vol 80 (10) ◽  
Author(s):  
ND Pugh ◽  
D Edwall ◽  
L Lindmark ◽  
KG Kousoulas ◽  
A Iyer ◽  
...  
Keyword(s):  
Virus Infection ◽  
Protective Effect ◽  
Influenza A ◽  
H1n1 Virus ◽  
Influenza A H1n1 ◽  
H1n1 Virus Infection

Narkolepsie nach Impfung gegen die pandemische Influenza A/H1N1/v?

Schlaf ◽  
2013 ◽  
Vol 2 (03) ◽  
pp. 154-160
Author(s):  
Geert Mayer ◽  
Brigitte Keller-Stanislawski ◽  
Doris Oberle
Keyword(s):  
Influenza A ◽  
Influenza A H1n1

Im Herbst/Winter 2009/2010 wurden etwa 30,8 Mio. Menschen in der Europäischen Union mit Pandemrix® gegen die pandemische Influenza A/H1N1/v geimpft. Der von GlaxoSmithKline produzierte Impfstoff war im September 2009 von der Europäischen Kommission als Pandemieimpfstoff zugelassen worden. Im Sommer 2010 wurde erstmals über Fälle einer Narkolepsie bei Kindern und Jugendlichen nach Impfung mit Pandemrix® in Schweden und Finnland berichtet.

Influenza A/H1N1 MF59-Adjuvanted Vaccine in Preterm and Term Children Aged 6 to 23 Months

PEDIATRICS ◽  
2011 ◽  
Vol 127 (5) ◽  
pp. peds.2010-1920d-peds.2010-1920d
Keyword(s):  
Influenza A ◽  
Adjuvanted Vaccine ◽  
Influenza A H1n1
Sign in / Sign up

Export Citation Format

Share Document